4oyq - Revision history

OCA at 07:07, 27 September 2023

OCA — Wed, 27 Sep 2023 07:07:39 GMT

←Older revision		Revision as of 07:07, 27 September 2023
Line 4:		Line 4:
	== Structural highlights ==		== Structural highlights ==
	<table><tr><td colspan='2'>[[4oyq]] is a 3 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4OYQ OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=4OYQ FirstGlance]. <br>		<table><tr><td colspan='2'>[[4oyq]] is a 3 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4OYQ OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=4OYQ FirstGlance]. <br>
-	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=1X2:6-ISOTHIOCYANATOHEXYLBENZENE'>1X2</scene>, <scene name='pdbligand=GOL:GLYCEROL'>GOL</scene>, <scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene></td></tr>	+	</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models\|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution\|Resolution]] 1.7Å</td></tr>
		+	<tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=1X2:6-ISOTHIOCYANATOHEXYLBENZENE'>1X2</scene>, <scene name='pdbligand=GOL:GLYCEROL'>GOL</scene>, <scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene></td></tr>
	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=4oyq FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4oyq OCA], [https://pdbe.org/4oyq PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=4oyq RCSB], [https://www.ebi.ac.uk/pdbsum/4oyq PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=4oyq ProSAT]</span></td></tr>		<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=4oyq FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4oyq OCA], [https://pdbe.org/4oyq PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=4oyq RCSB], [https://www.ebi.ac.uk/pdbsum/4oyq PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=4oyq ProSAT]</span></td></tr>
	</table>		</table>

OCA at 12:32, 1 February 2023

OCA — Wed, 01 Feb 2023 12:32:39 GMT

←Older revision		Revision as of 12:32, 1 February 2023
Line 1:		Line 1:

	==(6-isothiocyanatohexyl)benzene inhibitor complexed with Macrophage Migration Inhibitory Factor==		==(6-isothiocyanatohexyl)benzene inhibitor complexed with Macrophage Migration Inhibitory Factor==
-	<StructureSection load='4oyq' size='340' side='right' caption='[[4oyq]], [[Resolution\|resolution]] 1.70Å' scene=''>	+	<StructureSection load='4oyq' size='340' side='right'caption='[[4oyq]], [[Resolution\|resolution]] 1.70Å' scene=''>
	== Structural highlights ==		== Structural highlights ==
-	<table><tr><td colspan='2'>[[4oyq]] is a 3 chain structure with sequence from [~~http~~://en.wikipedia.org/wiki/~~Human Human~~]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4OYQ OCA]. For a <b>guided tour on the structure components</b> use [~~http~~://~~oca~~.~~weizmann.ac.il/oca-docs~~/fgij/fg.htm?mol=4OYQ FirstGlance]. <br>	+	<table><tr><td colspan='2'>[[4oyq]] is a 3 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4OYQ OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=4OYQ FirstGlance]. <br>
-	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=1X2:6-ISOTHIOCYANATOHEXYLBENZENE'>1X2</scene>, <scene name='pdbligand=GOL:GLYCEROL'>GOL</scene>, <scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene>~~</td></tr>~~	+	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=1X2:6-ISOTHIOCYANATOHEXYLBENZENE'>1X2</scene>, <scene name='pdbligand=GOL:GLYCEROL'>GOL</scene>, <scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene></td></tr>
-	~~<tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[3wns\|3wns]], [[3wnr\|3wnr]], [[3wnt\|3wnt]], [[4osf\|4osf]]</td></tr>~~	+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=4oyq FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4oyq OCA], [https://pdbe.org/4oyq PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=4oyq RCSB], [https://www.ebi.ac.uk/pdbsum/4oyq PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=4oyq ProSAT]</span></td></tr>
-	~~<tr id='gene'><td class="sblockLbl"><b>[[Gene\|Gene:]]</b></td><td class="sblockDat">MIF, GLIF, MMIF ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])~~</td></tr>	+
-	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[~~http~~://~~oca~~.~~weizmann.ac.il/oca-docs~~/fgij/fg.htm?mol=4oyq FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4oyq OCA], [~~http~~://pdbe.org/4oyq PDBe], [~~http~~://www.rcsb.org/pdb/explore.do?structureId=4oyq RCSB], [~~http~~://www.ebi.ac.uk/pdbsum/4oyq PDBsum], [~~http~~://prosat.h-its.org/prosat/prosatexe?pdbcode=4oyq ProSAT]</span></td></tr>	+
	</table>		</table>
	== Disease ==		== Disease ==
-	[~~[http~~://www.uniprot.org/uniprot/MIF_HUMAN MIF_HUMAN]] Genetic variations in MIF are associated with susceptibility to rheumatoid arthritis systemic juvenile (RASJ) [MIM:[~~http~~://omim.org/entry/604302 604302]]. An inflammatory articular disorder with systemic-onset beginning before the age of 16. It represents a subgroup of juvenile arthritis associated with severe extraarticular features and occasionally fatal complications. During active phases of the disorder, patients display a typical daily spiking fever, an evanescent macular rash, lymphadenopathy, hepatosplenomegaly, serositis, myalgia and arthritis.	+	[https://www.uniprot.org/uniprot/MIF_HUMAN MIF_HUMAN] Genetic variations in MIF are associated with susceptibility to rheumatoid arthritis systemic juvenile (RASJ) [MIM:[https://omim.org/entry/604302 604302]. An inflammatory articular disorder with systemic-onset beginning before the age of 16. It represents a subgroup of juvenile arthritis associated with severe extraarticular features and occasionally fatal complications. During active phases of the disorder, patients display a typical daily spiking fever, an evanescent macular rash, lymphadenopathy, hepatosplenomegaly, serositis, myalgia and arthritis.
	== Function ==		== Function ==
-	[~~[http~~://www.uniprot.org/uniprot/MIF_HUMAN MIF_HUMAN]] Pro-inflammatory cytokine. Involved in the innate immune response to bacterial pathogens. The expression of MIF at sites of inflammation suggests a role as mediator in regulating the function of macrophages in host defense. Counteracts the anti-inflammatory activity of glucocorticoids. Has phenylpyruvate tautomerase and dopachrome tautomerase activity (in vitro), but the physiological substrate is not known. It is not clear whether the tautomerase activity has any physiological relevance, and whether it is important for cytokine activity.<ref>PMID:15908412</ref> <ref>PMID:17443469</ref>	+	[https://www.uniprot.org/uniprot/MIF_HUMAN MIF_HUMAN] Pro-inflammatory cytokine. Involved in the innate immune response to bacterial pathogens. The expression of MIF at sites of inflammation suggests a role as mediator in regulating the function of macrophages in host defense. Counteracts the anti-inflammatory activity of glucocorticoids. Has phenylpyruvate tautomerase and dopachrome tautomerase activity (in vitro), but the physiological substrate is not known. It is not clear whether the tautomerase activity has any physiological relevance, and whether it is important for cytokine activity.<ref>PMID:15908412</ref> <ref>PMID:17443469</ref>
		+
		+	==See Also==
		+	*[[Macrophage inhibitory factor 3D structures\|Macrophage inhibitory factor 3D structures]]
	== References ==		== References ==
	<references/>		<references/>
	__TOC__		__TOC__
	</StructureSection>		</StructureSection>
-	[[Category: ~~Human~~]]	+	[[Category: Homo sapiens]]
-	[[Category: Dale~~, E J~~]]	+	[[Category: Large Structures]]
-	[[Category: Gamble~~, A B~~]]	+	[[Category: Dale EJ]]
-	[[Category: Gommans~~, A L~~]]	+	[[Category: Gamble AB]]
-	[[Category: Hampton~~, M B~~]]	+	[[Category: Gommans AL]]
-	[[Category: Nakatani, Y]]	+	[[Category: Hampton MB]]
-	[[Category: Rutledge~~, M T~~]]	+	[[Category: Nakatani Y]]
-	[[Category: Smith~~, R A.J~~]]	+	[[Category: Rutledge MT]]
-	[[Category: Spencer~~, E S~~]]	+	[[Category: Smith RAJ]]
-	[[Category: Tyndall~~, J D.A~~]]	+	[[Category: Spencer ES]]
-	[[Category: Vo~~, C T~~]]	+	[[Category: Tyndall JDA]]
-	[[Category: Wilbanks~~, S M]]~~	+	[[Category: Vo CT]]
-	~~[[Category: Cytokine]]~~	+	[[Category: Wilbanks SM]]
-	~~[[Category: Isomerase]]~~	+
-	~~[[Category: Isomerase-isomerase inhibitor complex]]~~	+
-	~~[[Category: Tautomerase~~]]	+

OCA at 15:15, 15 November 2017

OCA — Wed, 15 Nov 2017 15:15:52 GMT

←Older revision		Revision as of 15:15, 15 November 2017
Line 13:		Line 13:
	== Function ==		== Function ==
	[[http://www.uniprot.org/uniprot/MIF_HUMAN MIF_HUMAN]] Pro-inflammatory cytokine. Involved in the innate immune response to bacterial pathogens. The expression of MIF at sites of inflammation suggests a role as mediator in regulating the function of macrophages in host defense. Counteracts the anti-inflammatory activity of glucocorticoids. Has phenylpyruvate tautomerase and dopachrome tautomerase activity (in vitro), but the physiological substrate is not known. It is not clear whether the tautomerase activity has any physiological relevance, and whether it is important for cytokine activity.<ref>PMID:15908412</ref> <ref>PMID:17443469</ref>		[[http://www.uniprot.org/uniprot/MIF_HUMAN MIF_HUMAN]] Pro-inflammatory cytokine. Involved in the innate immune response to bacterial pathogens. The expression of MIF at sites of inflammation suggests a role as mediator in regulating the function of macrophages in host defense. Counteracts the anti-inflammatory activity of glucocorticoids. Has phenylpyruvate tautomerase and dopachrome tautomerase activity (in vitro), but the physiological substrate is not known. It is not clear whether the tautomerase activity has any physiological relevance, and whether it is important for cytokine activity.<ref>PMID:15908412</ref> <ref>PMID:17443469</ref>
-
-	==See Also==
-	*[[Macrophage inhibitory factor\|Macrophage inhibitory factor]]
	== References ==		== References ==
	<references/>		<references/>

OCA at 19:23, 11 August 2016

OCA — Thu, 11 Aug 2016 19:23:36 GMT

←Older revision		Revision as of 19:23, 11 August 2016
Line 1:		Line 1:
		+
	==(6-isothiocyanatohexyl)benzene inhibitor complexed with Macrophage Migration Inhibitory Factor==		==(6-isothiocyanatohexyl)benzene inhibitor complexed with Macrophage Migration Inhibitory Factor==
	<StructureSection load='4oyq' size='340' side='right' caption='[[4oyq]], [[Resolution\|resolution]] 1.70Å' scene=''>		<StructureSection load='4oyq' size='340' side='right' caption='[[4oyq]], [[Resolution\|resolution]] 1.70Å' scene=''>
Line 6:		Line 7:
	<tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[3wns\|3wns]], [[3wnr\|3wnr]], [[3wnt\|3wnt]], [[4osf\|4osf]]</td></tr>		<tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[3wns\|3wns]], [[3wnr\|3wnr]], [[3wnt\|3wnt]], [[4osf\|4osf]]</td></tr>
	<tr id='gene'><td class="sblockLbl"><b>[[Gene\|Gene:]]</b></td><td class="sblockDat">MIF, GLIF, MMIF ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])</td></tr>		<tr id='gene'><td class="sblockLbl"><b>[[Gene\|Gene:]]</b></td><td class="sblockDat">MIF, GLIF, MMIF ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])</td></tr>
-	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4oyq FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4oyq OCA], [http://www.rcsb.org/pdb/explore.do?structureId=4oyq RCSB], [http://www.ebi.ac.uk/pdbsum/4oyq PDBsum]</span></td></tr>	+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4oyq FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4oyq OCA], [http://pdbe.org/4oyq PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=4oyq RCSB], [http://www.ebi.ac.uk/pdbsum/4oyq PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=4oyq ProSAT]</span></td></tr>
	</table>		</table>
	== Disease ==		== Disease ==
Line 12:		Line 13:
	== Function ==		== Function ==
	[[http://www.uniprot.org/uniprot/MIF_HUMAN MIF_HUMAN]] Pro-inflammatory cytokine. Involved in the innate immune response to bacterial pathogens. The expression of MIF at sites of inflammation suggests a role as mediator in regulating the function of macrophages in host defense. Counteracts the anti-inflammatory activity of glucocorticoids. Has phenylpyruvate tautomerase and dopachrome tautomerase activity (in vitro), but the physiological substrate is not known. It is not clear whether the tautomerase activity has any physiological relevance, and whether it is important for cytokine activity.<ref>PMID:15908412</ref> <ref>PMID:17443469</ref>		[[http://www.uniprot.org/uniprot/MIF_HUMAN MIF_HUMAN]] Pro-inflammatory cytokine. Involved in the innate immune response to bacterial pathogens. The expression of MIF at sites of inflammation suggests a role as mediator in regulating the function of macrophages in host defense. Counteracts the anti-inflammatory activity of glucocorticoids. Has phenylpyruvate tautomerase and dopachrome tautomerase activity (in vitro), but the physiological substrate is not known. It is not clear whether the tautomerase activity has any physiological relevance, and whether it is important for cytokine activity.<ref>PMID:15908412</ref> <ref>PMID:17443469</ref>
		+
		+	==See Also==
		+	*[[Macrophage inhibitory factor\|Macrophage inhibitory factor]]
	== References ==		== References ==
	<references/>		<references/>

OCA at 14:57, 5 January 2015

OCA — Mon, 05 Jan 2015 14:57:47 GMT

←Older revision		Revision as of 14:57, 5 January 2015
Line 3:		Line 3:
	== Structural highlights ==		== Structural highlights ==
	<table><tr><td colspan='2'>[[4oyq]] is a 3 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4OYQ OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4OYQ FirstGlance]. <br>		<table><tr><td colspan='2'>[[4oyq]] is a 3 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4OYQ OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4OYQ FirstGlance]. <br>
-	</td></tr><tr><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=1X2:6-ISOTHIOCYANATOHEXYLBENZENE'>1X2</scene>, <scene name='pdbligand=GOL:GLYCEROL'>GOL</scene>, <scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene><br>	+	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=1X2:6-ISOTHIOCYANATOHEXYLBENZENE'>1X2</scene>, <scene name='pdbligand=GOL:GLYCEROL'>GOL</scene>, <scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene></td></tr>
-	<tr><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[3wns\|3wns]], [[3wnr\|3wnr]], [[3wnt\|3wnt]], [[4osf\|4osf]]</td></tr>	+	<tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[3wns\|3wns]], [[3wnr\|3wnr]], [[3wnt\|3wnt]], [[4osf\|4osf]]</td></tr>
-	<tr><td class="sblockLbl"><b>[[Gene\|Gene:]]</b></td><td class="sblockDat">MIF, GLIF, MMIF ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])</td></tr>	+	<tr id='gene'><td class="sblockLbl"><b>[[Gene\|Gene:]]</b></td><td class="sblockDat">MIF, GLIF, MMIF ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])</td></tr>
-	<tr><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4oyq FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4oyq OCA], [http://www.rcsb.org/pdb/explore.do?structureId=4oyq RCSB], [http://www.ebi.ac.uk/pdbsum/4oyq PDBsum]</span></td></tr>	+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4oyq FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4oyq OCA], [http://www.rcsb.org/pdb/explore.do?structureId=4oyq RCSB], [http://www.ebi.ac.uk/pdbsum/4oyq PDBsum]</span></td></tr>
-	<table>	+	</table>
	== Disease ==		== Disease ==
	[[http://www.uniprot.org/uniprot/MIF_HUMAN MIF_HUMAN]] Genetic variations in MIF are associated with susceptibility to rheumatoid arthritis systemic juvenile (RASJ) [MIM:[http://omim.org/entry/604302 604302]]. An inflammatory articular disorder with systemic-onset beginning before the age of 16. It represents a subgroup of juvenile arthritis associated with severe extraarticular features and occasionally fatal complications. During active phases of the disorder, patients display a typical daily spiking fever, an evanescent macular rash, lymphadenopathy, hepatosplenomegaly, serositis, myalgia and arthritis.		[[http://www.uniprot.org/uniprot/MIF_HUMAN MIF_HUMAN]] Genetic variations in MIF are associated with susceptibility to rheumatoid arthritis systemic juvenile (RASJ) [MIM:[http://omim.org/entry/604302 604302]]. An inflammatory articular disorder with systemic-onset beginning before the age of 16. It represents a subgroup of juvenile arthritis associated with severe extraarticular features and occasionally fatal complications. During active phases of the disorder, patients display a typical daily spiking fever, an evanescent macular rash, lymphadenopathy, hepatosplenomegaly, serositis, myalgia and arthritis.
Line 17:		Line 17:
	</StructureSection>		</StructureSection>
	[[Category: Human]]		[[Category: Human]]
-	[[Category: Dale, E J.]]	+	[[Category: Dale, E J]]
-	[[Category: Gamble, A B.]]	+	[[Category: Gamble, A B]]
-	[[Category: Gommans, A L.]]	+	[[Category: Gommans, A L]]
-	[[Category: Hampton, M B.]]	+	[[Category: Hampton, M B]]
-	[[Category: Nakatani, Y.]]	+	[[Category: Nakatani, Y]]
-	[[Category: Rutledge, M T.]]	+	[[Category: Rutledge, M T]]
-	[[Category: Smith, R A.J.]]	+	[[Category: Smith, R A.J]]
-	[[Category: Spencer, E S.]]	+	[[Category: Spencer, E S]]
-	[[Category: Tyndall, J D.A.]]	+	[[Category: Tyndall, J D.A]]
-	[[Category: Vo, C T.]]	+	[[Category: Vo, C T]]
-	[[Category: Wilbanks, S M.]]	+	[[Category: Wilbanks, S M]]
	[[Category: Cytokine]]		[[Category: Cytokine]]
	[[Category: Isomerase]]		[[Category: Isomerase]]
	[[Category: Isomerase-isomerase inhibitor complex]]		[[Category: Isomerase-isomerase inhibitor complex]]
	[[Category: Tautomerase]]		[[Category: Tautomerase]]

OCA at 02:57, 7 August 2014

OCA — Thu, 07 Aug 2014 02:57:35 GMT

←Older revision		Revision as of 02:57, 7 August 2014
Line 30:		Line 30:
	[[Category: Cytokine]]		[[Category: Cytokine]]
	[[Category: Isomerase]]		[[Category: Isomerase]]
		+	[[Category: Isomerase-isomerase inhibitor complex]]
	[[Category: Tautomerase]]		[[Category: Tautomerase]]

OCA at 12:46, 18 May 2014

OCA — Sun, 18 May 2014 12:46:17 GMT

←Older revision		Revision as of 12:46, 18 May 2014
Line 1:		Line 1:
-	~~{{STRUCTURE_4oyq\| PDB=4oyq \| SCENE= }}~~	+	==(6-isothiocyanatohexyl)benzene inhibitor complexed with Macrophage Migration Inhibitory Factor==
-	===(6-isothiocyanatohexyl)benzene inhibitor complexed with Macrophage Migration Inhibitory Factor===	+	<StructureSection load='4oyq' size='340' side='right' caption='[[4oyq]], [[Resolution\|resolution]] 1.70Å' scene=''>
-		+	== Structural highlights ==
-	==Disease==	+	<table><tr><td colspan='2'>[[4oyq]] is a 3 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4OYQ OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4OYQ FirstGlance]. <br>
		+	</td></tr><tr><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=1X2:6-ISOTHIOCYANATOHEXYLBENZENE'>1X2</scene>, <scene name='pdbligand=GOL:GLYCEROL'>GOL</scene>, <scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene><br>
		+	<tr><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[3wns\|3wns]], [[3wnr\|3wnr]], [[3wnt\|3wnt]], [[4osf\|4osf]]</td></tr>
		+	<tr><td class="sblockLbl"><b>[[Gene\|Gene:]]</b></td><td class="sblockDat">MIF, GLIF, MMIF ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])</td></tr>
		+	<tr><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4oyq FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4oyq OCA], [http://www.rcsb.org/pdb/explore.do?structureId=4oyq RCSB], [http://www.ebi.ac.uk/pdbsum/4oyq PDBsum]</span></td></tr>
		+	<table>
		+	== Disease ==
	[[http://www.uniprot.org/uniprot/MIF_HUMAN MIF_HUMAN]] Genetic variations in MIF are associated with susceptibility to rheumatoid arthritis systemic juvenile (RASJ) [MIM:[http://omim.org/entry/604302 604302]]. An inflammatory articular disorder with systemic-onset beginning before the age of 16. It represents a subgroup of juvenile arthritis associated with severe extraarticular features and occasionally fatal complications. During active phases of the disorder, patients display a typical daily spiking fever, an evanescent macular rash, lymphadenopathy, hepatosplenomegaly, serositis, myalgia and arthritis.		[[http://www.uniprot.org/uniprot/MIF_HUMAN MIF_HUMAN]] Genetic variations in MIF are associated with susceptibility to rheumatoid arthritis systemic juvenile (RASJ) [MIM:[http://omim.org/entry/604302 604302]]. An inflammatory articular disorder with systemic-onset beginning before the age of 16. It represents a subgroup of juvenile arthritis associated with severe extraarticular features and occasionally fatal complications. During active phases of the disorder, patients display a typical daily spiking fever, an evanescent macular rash, lymphadenopathy, hepatosplenomegaly, serositis, myalgia and arthritis.
-		+	== Function ==
-	==Function==	+
	[[http://www.uniprot.org/uniprot/MIF_HUMAN MIF_HUMAN]] Pro-inflammatory cytokine. Involved in the innate immune response to bacterial pathogens. The expression of MIF at sites of inflammation suggests a role as mediator in regulating the function of macrophages in host defense. Counteracts the anti-inflammatory activity of glucocorticoids. Has phenylpyruvate tautomerase and dopachrome tautomerase activity (in vitro), but the physiological substrate is not known. It is not clear whether the tautomerase activity has any physiological relevance, and whether it is important for cytokine activity.<ref>PMID:15908412</ref> <ref>PMID:17443469</ref>		[[http://www.uniprot.org/uniprot/MIF_HUMAN MIF_HUMAN]] Pro-inflammatory cytokine. Involved in the innate immune response to bacterial pathogens. The expression of MIF at sites of inflammation suggests a role as mediator in regulating the function of macrophages in host defense. Counteracts the anti-inflammatory activity of glucocorticoids. Has phenylpyruvate tautomerase and dopachrome tautomerase activity (in vitro), but the physiological substrate is not known. It is not clear whether the tautomerase activity has any physiological relevance, and whether it is important for cytokine activity.<ref>PMID:15908412</ref> <ref>PMID:17443469</ref>
-		+	== References ==
-	==~~About this Structure==~~	+	<references/>
-	~~[[4oyq]] is a 3 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4OYQ OCA].~~	+	__TOC__
-		+	</StructureSection>
-	~~==Reference~~==	+	[[Category: Human]]
-	<references ~~group="xtra"~~/><~~references~~/>	+
	[[Category: Dale, E J.]]		[[Category: Dale, E J.]]
	[[Category: Gamble, A B.]]		[[Category: Gamble, A B.]]

OCA at 14:30, 12 March 2014

OCA — Wed, 12 Mar 2014 14:30:55 GMT

←Older revision		Revision as of 14:30, 12 March 2014
Line 1:		Line 1:
-	~~'''Unreleased structure'''~~	+	{{STRUCTURE_4oyq\| PDB=4oyq \| SCENE= }}
		+	===(6-isothiocyanatohexyl)benzene inhibitor complexed with Macrophage Migration Inhibitory Factor===

-	~~The~~ entry ~~4oyq is ON HOLD~~	+	==Disease==
		+	[[http://www.uniprot.org/uniprot/MIF_HUMAN MIF_HUMAN]] Genetic variations in MIF are associated with susceptibility to rheumatoid arthritis systemic juvenile (RASJ) [MIM:[http://omim.org/entry/604302 604302]]. An inflammatory articular disorder with systemic-onset beginning before the age of 16. It represents a subgroup of juvenile arthritis associated with severe extraarticular features and occasionally fatal complications. During active phases of the disorder, patients display a typical daily spiking fever, an evanescent macular rash, lymphadenopathy, hepatosplenomegaly, serositis, myalgia and arthritis.

-	~~Authors~~: ~~Spencer, E~~.S.~~, Dale, E~~.J.~~, Gommans, A~~.L., ~~Vo, C.T~~., ~~Rutledge, M.T., Nakatani, Y., Gamble, A.B., Smith, R.A.J., Wilbanks, S.M., Hampton, M.B., Tyndall, J.D.A~~.	+	==Function==
		+	[[http://www.uniprot.org/uniprot/MIF_HUMAN MIF_HUMAN]] Pro-inflammatory cytokine. Involved in the innate immune response to bacterial pathogens. The expression of MIF at sites of inflammation suggests a role as mediator in regulating the function of macrophages in host defense. Counteracts the anti-inflammatory activity of glucocorticoids. Has phenylpyruvate tautomerase and dopachrome tautomerase activity (in vitro), but the physiological substrate is not known. It is not clear whether the tautomerase activity has any physiological relevance, and whether it is important for cytokine activity.<ref>PMID:15908412</ref> <ref>PMID:17443469</ref>

-	~~Description~~: (6-~~isothiocyanatohexyl)benzene inhibitor complexed with Macrophage Migration Inhibitory Factor~~	+	==About this Structure==
		+	[[4oyq]] is a 3 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4OYQ OCA].
		+
		+	==Reference==
		+	<references group="xtra"/><references/>
		+	[[Category: Dale, E J.]]
		+	[[Category: Gamble, A B.]]
		+	[[Category: Gommans, A L.]]
		+	[[Category: Hampton, M B.]]
		+	[[Category: Nakatani, Y.]]
		+	[[Category: Rutledge, M T.]]
		+	[[Category: Smith, R A.J.]]
		+	[[Category: Spencer, E S.]]
		+	[[Category: Tyndall, J D.A.]]
		+	[[Category: Vo, C T.]]
		+	[[Category: Wilbanks, S M.]]
		+	[[Category: Cytokine]]
		+	[[Category: Isomerase]]
		+	[[Category: Tautomerase]]

OCA: Protected "4oyq" [edit=sysop:move=sysop]

OCA — Wed, 19 Feb 2014 16:26:37 GMT

Protected "4oyq" [edit=sysop:move=sysop]

←Older revision

Revision as of 16:26, 19 February 2014

OCA: New page: '''Unreleased structure''' The entry 4oyq is ON HOLD Authors: Spencer, E.S., Dale, E.J., Gommans, A.L., Vo, C.T., Rutledge, M.T., Nakatani, Y., Gamble, A.B., Smith, R.A.J., Wilbanks, S....

OCA — Wed, 19 Feb 2014 16:26:36 GMT

New page: '''Unreleased structure''' The entry 4oyq is ON HOLD Authors: Spencer, E.S., Dale, E.J., Gommans, A.L., Vo, C.T., Rutledge, M.T., Nakatani, Y., Gamble, A.B., Smith, R.A.J., Wilbanks, S....

New page

'''Unreleased structure'''

The entry 4oyq is ON HOLD

Authors: Spencer, E.S., Dale, E.J., Gommans, A.L., Vo, C.T., Rutledge, M.T., Nakatani, Y., Gamble, A.B., Smith, R.A.J., Wilbanks, S.M., Hampton, M.B., Tyndall, J.D.A.

Description: (6-isothiocyanatohexyl)benzene inhibitor complexed with Macrophage Migration Inhibitory Factor